A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury.
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2013
At a glance
- Drugs Armodafinil (Primary)
- Indications Hypersomnia
- Focus Adverse reactions
- 17 Mar 2012 Additional locations (Germany, Spain) added as reported by European Clinical Trials Database record.
- 19 Nov 2010 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.